What is Adagrasib?

Adagrasib (Adagrasib) is a small molecule targeted drug that belongs to a class of anti-cancer drugs. It is primarily used to treat lung cancer patients who carry the KRAS G12C mutation, a common cancer driver gene mutation. KRASGene mutations are common in a variety of cancers, so the development of therapeutic drugs targeting this mutation is of great significance to the field of cancer treatment.

Adagrasib specifically acts on theKRAS G12C mutation, inhibiting the abnormal cell signaling pathways caused by this mutation. The mechanism of action of this drug is to bind to the KRAS G12C mutated protein and block its activity, thereby interfering with the proliferation and viability of cancer cells.

Clinical trials have shown that adagrasib has shown good efficacy in some lung cancer patients with KRAS G12C mutations, which is particularly important for those patients who have previously received other treatments and developed drug resistance. The development of this new drug marks an important advance in the treatment of KRAS mutation-related cancers, providing patients with more treatment options.

However, like all drugs, adagrasiib may be associated with some side effects. Like any cancer treatment regimen, patients need to be closely monitored and communicate with their doctors when using it to ensure optimal safety and efficacy during treatment. With further research and clinical practice, adagrasib is expected to become one of the important drugs in the treatment of lung cancer, improving patients' survival and quality of life.

Adagrasib is not currently available in the country, so patients cannot purchase it domestically and can only purchase adagrasib through overseas channels. Abroad, there is only the original American drug adagrasib, and the price is very high, as high as about 190,000 yuan.